27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The Ukiyo Project is a collaborative initiative between the Faculty of Fine Arts at the Complutense University of Madrid (UCM) and the Faculty of Psychology at the University of Guanajuato (Mexico), aimed at promoting emotional well-being and mental health in the university environment through art. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Als blutbasierter Biomarker zur Diagnose der Alzheimer-Krankheit gilt p-Tau217. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Down syndrome (DS), caused by trisomy of chromosome 21, exhibits significant phenotypic variability, including intellectual disability, early-onset Alzheimer disease (AD), congenital heart defects (CHDs), haematological malignancies, and immune dysregulation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Wissenschaftler*innen der Washington Universität in St. Louis untersuchten in dieser aktuellen Studie Machbarkeit und Sicherheit der Therapie mit dem monoklonalen Antikörper Lecanemab bei Patientinnen und Patienten mit früher symptomatischer Alzheimer-Krankheit. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Eine Möglichkeit zur Behandlung von beginnenden Alzheimer-Erkrankungen stellten Anti-Amyloid-Antikörper (AK) dar, die die Amyloidablagerungen im Gehirn reduzieren sollen. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mit der Zulassung von Lecanemab in Europa ist die Antikörpertherapie bei Alzheimer Krankheit (AD) hierzulande angekommen. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease is one of the causes of dementia that could make the patient lose their memories until they unable to do normal activities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This survey presents 50 research papers focussed on various techniques in Alzheimer classification techniques using 3D MRI images, and the categorisation of the techniques is made based on the fusion-based, convolutional neural network (CNN)-based, random forest (RF)-based and support vector machine (SVM)-based approaches. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
La enfermedad de Alzheimer (EA) fue descrita por primera vez en una mujer, Augusta D, cuyo caso reveló las características neuropatológicas clásicas de placas amiloides y ovillos neurofibrilares. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A doença de Alzheimer (DA) configura-se como a principal causa de demência em idosos, se tornando um dos maiores desafios da medicina moderna devido à sua alta prevalência e o impacto social associado. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a life-limiting condition and a leading cause of death in the UK and globally. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study examined how the COVID-19 pandemic altered the sociologic, individual, and biologic personhood of residents living with dementia in nursing homes, guided by Buron’s (2008) Personhood Model for Dementia Care (PMDC). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Researchers tested whether a tablet-based cognitive test (TabCAT) could substitute for traditional paper-and-pencil memory tests in people with early-onset Alzheimer's. Scores on the tablet's attention/executive tasks correlated strongly (above 0.7) with standard tests like the MMSE and MoCA, and one subtest could distinguish people with amyloid plaques from those without with good accuracy (AUC 0.82). 5 key findings →
Design: cross-sectional Participants: 475 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Trontinemab is designed with a molecular 'shuttle' that helps it cross into the brain more efficiently than older anti-amyloid antibodies, aiming for faster plaque removal at lower doses. 5 key findings →
Design: phase-2-trial Participants: 13 Evidence: early
Full summary, score breakdown and related studies → Original source
Mivelsiran takes a completely different approach from antibody drugs: it's injected into the spinal fluid and uses RNA interference to tell brain cells to make less of the amyloid precursor protein in the first place, rather than clearing plaques after they form. 5 key findings →
Design: phase-1-trial Participants: 19 Evidence: preliminary
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease manifests through heterogeneous progression patterns across diverse populations, yet current predictive models fail to capture this complexity while maintaining clinical interpretability. 4 key findings →
Design: longitudinal study Participants: 1,669 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Adults with Down syndrome carry high risk of developing Alzheimer’s disease and efforts to include this population in clinical trials remain limited. 4 key findings →
Design: longitudinal study Participants: 237 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Anti-amyloid immunotherapy is used to treat Alzheimer disease (AD) with moderate benefits and potentially serious side effects due to amyloid related imaging abnormality with effusions/edema (ARIA-E). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The integration of artificial intelligence in medical image classification has significantly advanced disease detection. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The “WarioWare: Move It!” intervention significantly improved physical flexibility, joint range of motion, motor coordination, hand dexterity, and cognitive function among older adults with mild cognitive impairment or dementia residing in rural LTCFs. 5 key findings →
Participants: 232 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite elevated risk profiles for dementia, Black women are often absent in cultural narratives about dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We examine the scaling of Small Area Fair Market Rents (SAFMRs) of Housing Choice Voucher (HCV) program in 2018. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
At baseline, higher AgeAccelPheno was associated with lower amyloid-β42 to amyloid-β40 (Aβ42:Aβ40) ratio, and higher AgeAccelGrim2 was associated with elevated neurofilament light (NfL). 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI) is a major risk factor for neurodegenerative diseases, including Alzheimer's disease (AD), yet the mechanistic link remains unclear. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →